Available:*
Library | Item Barcode | Call Number | Material Type | Item Category 1 | Status |
|---|---|---|---|---|---|
Searching... | 30000010335233 | RC271.C5 C364 2014 | Open Access Book | Book | Searching... |
On Order
Summary
Summary
Cancer Drug Design and Discovery, Second Edition is an important reference on the underlying principles for the design and subsequent development of new anticancer small molecule agents. New chapters have been added to this edition on areas of particular interest and therapeutic promise, including cancer genomics and personalized medicine, DNA-targeted agents and more. This book includes several sections on the basic and applied science of cancer drug discovery and features those drugs that are now approved for human use and are in the marketplace, as well as those that are still under development. By highlighting some of the general principles involved in taking molecules through basic science to clinical development, this book offers a complete and authoritative reference on the design and discovery of anticancer drugs for translational scientists and clinicians involved in cancer research.
Author Notes
Stephen Neidle, DSc, PhD, ARCS, FRSC, Director of Cancer Research UK Biomolecular Structure Group, Director of the Centre for Cancer Medicines, Professor of Chemical Biology, The School of Pharmacy, University College London, UK
Table of Contents
| IntroductionStephen Neidle |
| ForewordHilary Calvert |
| Part I Basic Principles and methodology |
| Modern cancer drug discovery: integrating targets, technologies and treatmentsPaul Workman and Ian Collins |
| Pharmacogenomics and personalised medicines in cancer treatmentWei-Peng Yong and Ross Soo and Federico Innocenti |
| Structural biology and anticancer drug designPuja Pathuri and David Norton and Henriette Willems and Dominic Tisi and Harren Jhoti |
| Part II Drugs in the laboratory and clinic |
| Temozolomide: from cytotoxic to molecularly-targeted agentMalcolm Stevens |
| Temozolomide: patents and the perils of inventionMalcolm Stevens |
| A new generation of cell-targeted drugs for cancer treatmentPaola B. Arimondo and Nicolas Guilbaud and Christian Bailly |
| Inhibition of DNA repair as a therapeutic targetStephany Veuger and Nicola J Curtin Inhibitors of tumour angiogenesis and Adrian L. Harris and Daniele G Generali |
| The Renaissance of CYP17 Inhibitors for the Treatment of Prostate CancerQingzhong Hu and Rolf W. Hartmann |
| Apoptosis in Cancer: Mechanisms, Deregulation and Therapeutic TargetingZahid H Siddik |
| Targeting the MDM2-p53 protein-protein interaction: design, discovery and development of novel anticancer agentsIan R Hardcastle |
| Targeting altered metabolism - emerging cancer therapeutic strategyMinsuh Seo and Robert Blake Crochet and Yong-Hwan Lee |
| Inhibitors of the Phosphatidylinositol 3-kinase (PI3K) PathwayWilliam A Denny and Gordon W. Rewcastle |
| Antibody-drug conjugates delivering DNA cytotoxicsJohn A Hartley |
| Inhibition of telomerase: promise, progress and potential pitfallsChristopher G. Tomlinson and Scott B. Cohen and Tracy M. Bryan |
| Targeting B-RAF: the discovery and development of B-RAF inhibitorsPhillip A Harris |
| Part III The reality of cancer drugs in the clinic |
| Failure Modes in Anticancer Drug Discovery and DevelopmentRichard A. Walgren and Christopher. A. Slapak |
| Anticancer drug registration and regulation: current challenges and possible solutionsDavid Taylor and Erling Donnelly and Silvia Chioato |
